

Form 605

Corporations Act 2001

Section 671B

Notice of ceasing to be a substantial holderTo Company Name/Scheme AMPLIA THERAPEUTICS LIMITEDACN/ARSN 165 160 841**1. Details of substantial holder(1)**Name CHRISTOPHER CARL COLLINS

ACN/ARSN (if applicable) _____

The holder ceased to be a
substantial holder on07/10/2019

The previous notice was given to the company on

08/05/2018

The previous notice was dated

08/05/2018**2. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change(5)	Class (6) and number of securities affected	Person's votes affected
20 / 6 / 2018	Christopher Collins	On-market sale		60,344	Christopher Collins
26 / 9 / 2019	Christopher Collins	On-market sale		400,000	Christopher Collins
01/10/2019	Christopher Collins	Off-market Transfer		3,329,570	Christopher Collins

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association


4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Christopher Carl Collins	9660 Cobblestone Drive Clarence New York 14031 USA

Signatureprint name Christopher Carl Collinscapacity Shareholder

sign here

date 31 / 10 / 2019